Build your own system
Chapterized scipts
Popular packages
One-pager
Narrative development
Pricing options
Team structure
Partnering
Bespoke Animation Capabilities
Additional capes, work samples, testimonials (Appendix)
Chief Medical Strategy
Chief Science Officer at MoA, MoD animation Department
CEO, Founder,
Art Director
Strategic Partnerships
PRECLINICAL
DEVELOPMENT
CLINICAL DEVELOPMENT
Phase 1 | Phase 2 | Phase 3
LAUNCH /
POST LAUNCH
BRAND MATURITY
Phase 4
Trusted by Top-20 Pharma and 100+ small and medium Biotechs
MoD/MoA animation
and illustration
Corporate & IR decks
Field content
Congress booth programs
Websites
75% of routine steps are automated using proprietary software and machine learning.
The most efficient production pipeline with 3x faster delivery.
Data-driven feedback loop optimization for every asset.
Live strategy workshops
Scientific communications
platform (ScP), lexicon
Content optimization
and channel planning
Microcontent planning
and development:
Custom apps
Veeva-trained staff
Animated data
15-second videos
Visual digests
Clonal hematopoiesis (CHIP): mechanisms and consequences
The leukemic Bone Marrow niche and pathogenesis of AML
BCL2: genetic alteration and role in lymphoid malignancies
Mechanisms of action: CAR-T cells
Mechanisms of action: Bispecific Abs
Mechanisms of action: small molecules inhibitors
The role of epigenetic mechanisms in hematological malignancies
Techniques: NGS (TIF: PH)
Techniques: qPCR (TIF: PH)
Techniques: single cell genetics (TIF: pH)
Von Willebrand factor structure and defects
AI in hematology: AI-based digital morph. analysis
Synthetic patients in clinical trials
RBCs: Hb linking and releasing O2
10 Universities:
5 Publishers:
15+ Patient Organizations
and Foundations
INCLUDING TWO UNIQUE
The most advanced animation type on the market, based on computational biology methods. Science-grade molecular simulations for unprecedented accuracy.
UNIQUE SCIENTIFIC-GRADE TYPE
Featured:
UNIQUE SCIENTIFIC-GRADE TYPE
Featured:
Awarded:
UNIQUE SCIENTIFIC-GRADE TYPE
Main 3D is the most universal animation type. It's scientifically rigorous, eye-catching, and very cinematic. It's a great match for most MoAs and MoDs for IR needs, alongside HCP communications.
The usual Main 3D animation type in combination with 2D elements. This is an excellent option for MoAs where there's a need to incorporate research data, schematics, or other additional information.
UNIQUE APPROACH
A relatively simple, yet still eye-catching 2D animation style is an ideal option for explainer animations, platform or AI-based technologies, alongside cases where IP details must not be disclosed.
Clear, simple, a eye-catching 2D animation style is an ideal option
for explainer animations, HCP and patient education videos
Clear, simple, a eye-catching 2D animation style is an ideal option
for explainer animations, HCP and patient education videos
This type is designed specifically for projects with tight deadlines. Through optimization, we achieve a rapid turnaround without compromising quality or scientific accuracy. The fastest type of 3D animation to produce on the market.
UNIQUE
A unique combination of scientific-grade molecular simulations that accurately represents real molecular interactions and states, with all the benefits of 2D animation —affordable and fast to produce. Unbeatable quality-to-cost-per-second ratio.
UNIQUE
Top 20 Pharma undisclosed client, anonymized data
Animation type:
Clinical trial update
Time:
1 week
Client:
Undisclosed
We adopt a layered approach for our video animations, adding a customizable 2D layer atop the main 3D or high-end 3D visuals. This method allows for rapid repurposing of content for any event or audience, often with negligible additional costs.
A modular structure for our assets facilitates easy repurposing for different media and audiences with minimal effort. This flexibility significantly enhances each asset’s value and lifespan.
By streamlining our processes through hundreds of projects and automating outdated practices with proprietary software, we not only achieve superior quality at competitive prices, but also deliver projects up to three times faster.
We carefully select from our range of six main animation types and twenty subtypes to ensure we use the most effective and cost-efficient animation for each scene. Typically, a project might incorporate two to four different animation styles.
Confidential — Not for Public Consumption or Distribution
| OPTIONS | COMPLEXITY | LENGTH |
|---|---|---|
|
Option A |
High-end type The most advanced animation type on the market, based on computational biology methods. Science-grade molecular simulations for unprecedented accuracy. |
~ 3.5 min |
|
Option B |
Main3D + 2D types The most universal animation type. It's scientifically rigorous, eye-catching, and very cinematic combined with a relatively simple, yet still eye-catching 2D animation style |
~ 3.5 min |
|
Option C |
Main3D, Deck3D, 2D types Combines the most universal, eye-catching 2D, and Deck3D eye-catching like our main 3D, but slightly less detailed backgrounds |
~ 3.5 min |
|
Option D |
Main3D + 2D shortened version The most universal animation type. It's scientifically rigorous, eye-catching, and very cinematic combined with a relatively simple, yet still eye-catching 2D animation style |
~ 2.5 min |
UNIQUE
BuildYourOwn™ — A Unique Pricing System
or
Most Chosen by Clients
Development of 1 infographic leave behind for multichannel use:
Hours and OOPs assume Visual Science to:
Development of a front back leave behind for multichannel use
Utilize existing JNJ Medical look/feel to develop layout
Content and imagery leveraged from video animation
Introduction to AML
Mutations in develpment of AML
KMT2A in AML
NMP1 in AML
Mennin as a druggable target in AML
Menin inhibitors and advantages of Bleximenib
Includes full editorial QC (copyedit, annotation and fact check) prior to each Med/Legal review
Client reviews assume 3 rounds of client revisions (1 round for outline review, 1 prior to submission of layout for MLR review, 1 round prior to final MLR approval). Visual Science to prepare for 2 rounds of Med/Legal submission; 1 for review for revisions; BGB to upload into Veeva for final approval
OOP Assumptions assume art usage rights, artist illustration, and retouching.
Price range: $25-$30k
Confidential — Not for Public Consumption or Distribution
A cross-functional strategic exercise
to define the clinical value and scientific
rationale of your molecule
A clear and compelling story
scalable for all external audiences
An internal asset that expedites
approval of external facing assets
Confidential — Not for Public Consumption or Distribution
Medical Affairs
Commercial
Regulatory
Clinical Program
IR & Corporate Comm.
Payer/Market Access/HEOR
The overarching story
of your molecule and
the clinical challenge
it solves
Breaks down the narrative into 5-6 discrete topics,
such as unmet need,
MOA, and clinical
trial results
5-8 evidence driven Statements which
support each
Concept
Hyperlinked and annotated reference
that support each statement
Identifiable Evidence
Gaps Needed to Tell
Full Story of your product
Confidential — Not for Public Consumption or Distribution
The VS medical team will review available evidence, and generate
the brief that summarizes
the project plan.
DEFINE THE STRATEGY
VALIDATE & ROLLOUT
VALIDATE & ROLLOUT
ANALYZE THE
LANDSCAPE
Download
Meeting
Mindset
workshop
Draft Core
Concepts
Draft Scientific Statements
Curate Scientific Evidence
Expert
Validation
Functional
Roll-out
Our team and
your internal stakeholders will workshop current audience mindsets, and ID changes
that can ease product uptake.
Informed by the mindset workshop,
VS will draft
an overarching scientific narrative and core concepts to be reviewed by the core team.
With the core concepts settled,
we draft scientific statements to support each
core concepts
and review with
the core team.
The VS team will align & annotate evidence to
agreed scientific statements.
Once evidence is finalized, it is key
to validate with
your audience.
Once finalized,
we recommend reengaging the extended team
to review and adopt.
The core team will align with
Visual Science and drive the effort kickoff to delivery.
The Visual Science team will moderate this process taking in and adjudicating perspectives.
Extended team includes stakeholders from all internal functions, to take
in perspectives from multiple lenses.
KOLs for veracity, community to test resonance.
Confidential — Not for Public Consumption or Distribution
Early Stage (Clin-P1)
Mid Stage (P1-P2)
Late Stage (P2-Pre-Launch)
Sean Rooney, PhD
Chief Medical Strategy
Chief Executive Officer
Michael Russo
Head, Strategic Partnerships
Ivan K., M.Sc
Jenn Terrell, MBA
Yury Stefanov, PhD
Nancy Miller
Marianna Jain
Lori Magnelli
Marni Kelman. M.Sc
Rich Friel
Lori Magnelli
Nicole Cooper
Dan Purkis
Qais Saket
Max Kulemza
Tobias Van Schnider
* All employess are full time
Alex Whitewood
Ihor Cherno
Nicole Cooper
Appendix
Type:
Series B deck
Time:
6 weeks
Scope:
IR, scientific flow optimization, design, illustrations, animations
Type:
Corporate deck for public company
Time:
4 weeks
Scope:
Design, illustrations, animations
Type:
Corporate deck for public company
Time:
5 weeks
Scope:
Scientific flow optimization, design, illustrations, animations
Type:
High-end 3D infographics for deck
Time:
1 week
Type:
2D infographics for deck
Time:
1 week
NASDAQ: APGE
Type:
Corporate website for public company
Time:
10 weeks
Scope:
Design, development, illustrations, animations
NASDAQ: ENVB
Type:
Corporate website for public company
Time:
9 weeks
Scope:
Design, development, illustrations, animations
For congress support and in field communications
UNIQUE
UNIQUE
UNIQUE TECHNOLOGY
Mobile-first version of the poster
PPT slides with key takeaways
High-end 3D + Pathway 3D
12 days — yes, days!
10 weeks
High-end 3D
High-end 3D
12 weeks
2D
8 weeks
High-end 3D
10 weeks
High-end 3D
10 weeks
3D
7 weeks
Main 3D
8 weeks
High-end 3D
8 weeks
High-end 3D
High-end 3D
9 weeks
3D
4 weeks
Simplified 3D